Overcoming Drug Resistance in Ovarian Cancer | Dana-Farber Cancer Institute

Treatment Advances in Ovarian Cancer RecurrenceПодробнее

Ovarian Cancer at a Crossroads | Dana-Farber Cancer InstituteПодробнее

Overcoming Ovarian Cancer Recurrence and Drug Resistance - Emerging ResearchПодробнее

The Power of Combination Drug Therapy for Ovarian Cancer | Dana-Farber Cancer InstituteПодробнее

What is Ovarian Cancer? | Dana-Farber Cancer InstituteПодробнее

The Promise of Immunotherapy for Ovarian Cancer | Dana-Farber Cancer InstituteПодробнее

Overcoming drug resistance in ovarian cancerПодробнее

Overcoming resistance to PARPi in BRCA1-deficient breast cancer with STING agonistsПодробнее

The Genomics of Ovarian Cancer: Overcoming Drug Resistance | Dana-Farber Cancer InstituteПодробнее

SABCS23: Kate Dibble, PhD, discusses ovarian function suppression | Dana-Farber Cancer InstituteПодробнее

A Tremendous Pressure To Survive | Dana-Farber Cancer InstituteПодробнее

Dr. Joyce F. Liu on ovarian cancer clinical trial results | Dana-Farber Cancer InstituteПодробнее

Understanding and Overcoming PARP Inhibitor ResistanceПодробнее

The Latest in Ovarian Cancer Treatment | Dana-Farber Cancer InstituteПодробнее

Antibody-drug conjugates in gynecological cancersПодробнее

Drug Delivery & Nanotechnology: Better & More Efficient Therapies for Ovarian Cancer | Dana-FarberПодробнее

Can Aspirin Prevent Ovarian Cancer?Подробнее

Dr. Joyce Liu -- ASCO 2014 | Dana-Farber Cancer InstituteПодробнее

Live Webchat: The Latest in Ovarian Cancer Treatment and ResearchПодробнее